MapLight Therapeutics Nears Key Phase 2 Readouts in Q3 2026, Extends Cash Runway Through 2027
MPLT sits 48% above its 52-week low of $12.24.
Summary
MapLight Therapeutics reported its fourth quarter and full year 2025 financial results and provided a comprehensive business update. The company announced a strong cash position of $453.1 million as of December 31, 2025, which is expected to fund operations through 2027, providing significant financial runway. Operationally, MapLight completed enrollment for its ML-004 Phase 2 IRIS trial for Autism Spectrum Disorder and expects to reach target enrollment for its ML-007C-MA Phase 2 ZEPHYR trial for schizophrenia in April 2026. Crucially, topline results for both the IRIS and ZEPHYR trials are anticipated in the third quarter of 2026. These upcoming Phase 2 data readouts represent significant catalysts for the clinical-stage biopharmaceutical company, and the extended cash runway provides stability ahead of these critical milestones. Investors will be closely watching the Q3 2026 results for potential impacts on the company's valuation and future development path.
At the time of this announcement, MPLT was trading at $18.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $823.1M. The 52-week trading range was $12.24 to $21.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.